NASDAQ:CRNX

Crinetics Pharmaceuticals Stock Forecast, Price & News

$15.24

+0.02 (+0.13 %)

(As of 01/25/2021 12:00 AM ET)

Add

Compare

Today's Range

$14.21

Now: $15.24▼

$15.35

50-Day Range

$13.05

MA: $14.04▼

$15.22

52-Week Range

$10.63

Now: $15.24▼

$24.46

Volume71,000 shs

Average Volume146,574 shs

Market Capitalization$501.73 million

P/E RatioN/A

Dividend YieldN/A

Beta1.24

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly and neuroendocrine tumors. The company is also developing CRN01941, an oral selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors; an oral selective nonpeptide somatostatin type 5 receptor agonist for treating congenital hyperinsulinism; and an oral adrenocorticotrophic hormone antagonist for the treatment of cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was founded in 2008 and is headquartered in San Diego, California.

MarketRank^™

Overall MarketRank^™

1.61 out of 5 stars

Medical Sector

296th out of 1,922 stocks

Pharmaceutical Preparations Industry

151st out of 771 stocks

3.3 Analyst's Opinion

Consensus Rating
Crinetics Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $36.00, Crinetics Pharmaceuticals has a forecasted upside of 136.2% from its current price of $15.24.
Amount of Analyst Coverage
Crinetics Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.2 Community Rank

Outperform Votes
Crinetics Pharmaceuticals has received 88 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Crinetics Pharmaceuticals has received 109 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Crinetics Pharmaceuticals has received 55.33% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Crinetics Pharmaceuticals and other stocks. Vote “Outperform” if you believe CRNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CRNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Crinetics Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Crinetics Pharmaceuticals does not have a long track record of dividend growth.

2.5 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Crinetics Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $12,600.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.10% of the stock of Crinetics Pharmaceuticals is held by insiders.
Percentage Held by Institutions
92.15% of the stock of Crinetics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Crinetics Pharmaceuticals are expected to decrease in the coming year, from ($2.35) to ($2.36) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Crinetics Pharmaceuticals is -6.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Crinetics Pharmaceuticals is -6.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Crinetics Pharmaceuticals has a P/B Ratio of 3.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CRNX

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.crinetics.com

Phone858-450-6464

Employees68

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio21.98

Quick Ratio21.98

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.19 million

Price / Sales421.62

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.84 per share

Price / Book3.15

Profitability

EPS (Most Recent Fiscal Year)($2.09)

Net Income$-50,420,000.00

Net MarginsN/A

Return on Equity-43.35%

Return on Assets-39.73%

Miscellaneous

Outstanding Shares32,922,000

Market Cap$501.73 million

Next Earnings Date3/8/2021 (Estimated)

OptionableNot Optionable

$15.24

+0.02 (+0.13 %)

(As of 01/25/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CRNX News and Ratings via Email

Sign-up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter.

Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

How has Crinetics Pharmaceuticals' stock price been impacted by Coronavirus?

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CRNX stock has decreased by 1.7% and is now trading at $15.24.
View which stocks have been most impacted by COVID-19.

Is Crinetics Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Crinetics Pharmaceuticals?

Wall Street analysts have given Crinetics Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Crinetics Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 8th 2021.
View our earnings forecast for Crinetics Pharmaceuticals.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) issued its earnings results on Wednesday, November, 11th. The company reported ($0.56) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.03.
View Crinetics Pharmaceuticals' earnings history.

What price target have analysts set for CRNX?

3 brokers have issued twelve-month price objectives for Crinetics Pharmaceuticals' shares. Their forecasts range from $30.00 to $42.00. On average, they expect Crinetics Pharmaceuticals' stock price to reach $36.00 in the next year. This suggests a possible upside of 136.2% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Crinetics Pharmaceuticals' key competitors?

Some companies that are related to Crinetics Pharmaceuticals include Prestige Consumer Healthcare (PBH), Kura Oncology (KURA), Dicerna Pharmaceuticals (DRNA), NGM Biopharmaceuticals (NGM), PMV Pharmaceuticals (PMVP), Revance Therapeutics (RVNC), Myovant Sciences (MYOV), Madrigal Pharmaceuticals (MDGL), Y-mAbs Therapeutics (YMAB), Olema Pharmaceuticals (OLMA), Zentalis Pharmaceuticals (ZNTL), Kronos Bio (KRON), uniQure (QURE), Generation Bio (GBIO) and Rhythm Pharmaceuticals (RYTM).
View all of CRNX's competitors.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:

Dr. R. Scott Struthers, Founder, Pres, CEO & Director (Age 59, Pay $715.39k)
Mr. Marc J. C. Wilson, CFO & Sec. (Age 42, Pay $450k)
Dr. Alan S. Krasner, Chief Medical Officer (Age 58, Pay $571.97k)
Dr. Yun-Fei Zhu, Founder & VP of Chemistry (Age 58)
Dr. Stephen F. Betz, Co-Founder & VP of Biology (Age 55)
Ms. Adriana Cabre, VP of HR
Dr. Ajay Madan DABT, Ph.D., D.A.B.T., Chief Devel. Officer (Age 53)
Mr. Peter Trainer BSc, MBChB, M.D., FRCP, VP of Clinical Endocrinology
Ms. Gina Ford M.B.A., R.Ph., RPh, VP of Corp. Strategy & Commercial Planning

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray served as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $15.24.

How big of a company is Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals has a market capitalization of $501.73 million and generates $1.19 million in revenue each year. The company earns $-50,420,000.00 in net income (profit) each year or ($2.09) on an earnings per share basis. Crinetics Pharmaceuticals employs 68 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]

This page was last updated on 1/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here